Novavax (NVAX) Enterprise Value (2010 - 2026)

Novavax's Enterprise Value history runs 17 years deep, the most recent figure standing at -$790.3 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 65.07% year-over-year to -$790.3 million in Q1 2026; TTM through Mar 2026 was -$790.3 million, a 65.07% decrease from a year earlier, with the FY2025 full-year figure at -$505.3 million, down 25.23% from the prior year.
• Enterprise Value fell to -$790.3 million in Q1 2026 per NVAX's latest filing, from -$505.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$10.3 million in Q2 2022 and bottomed at -$1.6 billion in Q1 2022.
• The 5-year median for Enterprise Value is -$505.9 million (2023), against an average of -$545.6 million.
• Across the five-year window, Enterprise Value jumped 99.5% in 2022 and tumbled 5937.13% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$10.3 million in 2022, then slumped by 5417.86% to -$568.5 million in 2023, then grew by 29.02% to -$403.5 million in 2024, then fell by 25.23% to -$505.3 million in 2025, then slumped by 56.4% to -$790.3 million in 2026.
• Per Business Quant, the three latest NVAX Enterprise Value figures stand at -$790.3 million (Q1 2026), -$505.3 million (Q4 2025), and -$762.9 million (Q3 2025).